Phenylbutazone

  • TRADE NAMES: Butatab; Butazolidine; Butazone
  • INDICATIONS: Ankylosing spondylitis, gouty arthritis, osteoarthritis, rheumatoid arthritis
  • CLASS: Non-steroidal anti-inflammatory (NSAID)
  • HALF-LIFE: 54–99 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Anticoagulants, antidiabetics, barbiturates, Chlorpheniramine, corticosteroids, Digoxin, Gliclazide, Lithium, Methotrexate, Methylphenidate, Phenytoin, Rifampin, sulfonamides

NSAIDs may cause an increased risk of serious cardiovascular and gastrointestinal adverse events, which can be fatal. This risk may increase with duration of use.

Our database has 32 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CENTRAL NERVOUS SYSTEM
GASTROINTESTINAL/HEPATIC
HEMATOLOGIC


Page last updated 03/02/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric